Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

February 3, 2017

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Chronic Myeloid LeukemiaCMLPhiladelphia Chromosome-positive Acute Lymphoblastic LeukemiaPh+ ALL
Trial Locations (19)

1000

Institut Jules Bordet, Brussels

1020

CHU Brugmann, Brussels

1070

Hopital Erasme, Brussels

1090

UZ Brussel, Brussels

1200

Clinique universitaires Saint-Luc, Brussels

2060

ZNA Stuyvenberg, Antwerp

2300

AZ Turnhout St-Elisabeth, Turnhout

2650

UZ Antwerpen, Antwerp

2930

AZ Klina, Brasschaat

3000

UZ Leuven, Leuven

3500

Jessa Ziekenhuis, Hasselt

3600

Ziekenhuis Oost Limburg (ZOL), Ghent

4000

CHU Sart Tilman Liège, Liège

4800

CHR La Tourelle, Verviers

5530

CHU/UCL Namur Mont-Godinne, Yvoir

6110

CHU Charleroi Vésale, Montigny-le-Tilleul

7100

Hopital Jolimont, Haine-Saint-Paul

8000

AZ St-Jan Brugge, Bruges

8500

AZ Groeninge, Kortrijk

All Listed Sponsors
lead

Incyte Biosciences Benelux

INDUSTRY

NCT03678454 - Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | Biotech Hunter | Biotech Hunter